PPRH2

PPRH2 (specifically HpKras-P2) is a polypurine reverse Hoogsteen hairpin (PPRH) oligonucleotide designed to target the KRAS oncogene. Developed by researchers at the University of Barcelona, PPRHs are a novel class of gene-silencing agents consisting of two polypurine domains linked by a thymidine loop. These molecules bind to specific polypyrimidine tracks in the genomic DNA—typically within the promoter region—through Hoogsteen base pairing, forming a stable triplex structure that displaces the fourth DNA strand and inhibits transcription. PPRH2 specifically targets the KRAS promoter to downregulate its expression. In preclinical studies, particularly in ovarian and lung cancer models, PPRH2 has demonstrated the ability to inhibit cell proliferation, reduce 3D spheroid growth, and significantly enhance the efficacy of chemotherapeutic agents such as cisplatin and paclitaxel by overcoming chemoresistance associated with KRAS overexpression.

Other names

KRAS-targeting PPRHpolypurine reverse Hoogsteen hairpin 2HpKras-P2 oligonucleotideHpKras-P-2 oligonucleotideHpKras-P 2 oligonucleotide